CPRX

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.

Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 34.00 USD with a low forecast of 33.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Catalyst Pharmaceuticals Inc revenue for the last quarter amounts to 148.39M USD, increased 15.31 % YoY.

Catalyst Pharmaceuticals Inc. EPS for the last quarter amounts to 0.42 USD, increased 20.00 % YoY.

Catalyst Pharmaceuticals Inc (CPRX) has 181 emplpoyees as of January 09 2026.

Today CPRX has the market capitalization of 2.78B USD.